Genprex appoints Board member Jose Moreno Toscano as Non-Executive Chairman

– USA, TX –  Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the appointment of current Board member Jose Moreno Toscano as Non-Executive Chairman following the sudden passing of the co-founder and Chairman Rodney Varner.

His appointment follows the recent appointment of Ryan Confer to serve as President and CEO. Mr. Confer was also appointed to the Board of Directors.

About Jose A. Moreno Toscano

Before he was appointed Chairman, Mr. Moreno Toscano had served on Genprex’s Board of Directors since March 2020. Since April 2018, he has been CEO of LFB USA Inc, the US subsidiary of LFB Group, a global integrated biopharmaceutical company, and he has more than 20 years of experience in the pharmaceutical and biotechnology industries, building, developing g, and transforming organizations. Mr. Moreno Toscano has a successful track record of identifying and capitalizing on opportunities to drive exponential revenue growth and market expansion, revitalizing underperforming operations, and establishing foundations for successful start-up operations. His experience includes strategic planning, corporate restructuring, business development, M&A, investor relations, and general management.

Mr. Moreno Toscano commented: “On behalf of Genprex’s Board of Directors, we wish to express our support for Ryan as Genprex’s new President and CEO. We have worked closely with Ryan over the last several years, and we have seen his robust leadership skills and exceptional operational organization. He has strengthened the company’s operational and financial foundation, bolstered the company’s talent and culture, added value in every company department and has continuously advanced the company’s strategies year after year. I look forward to working alongside Ryan and our other fellow directors in my role as Chairman in what I believe will be a transformational time for Genprex.”

About Genprex, Inc.

Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies to provide novel treatment approaches. Genprex’s oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins deficient in the tumor. The Company’s lead product candidate, Reqorsa® Immunogene Therapy (quaratusugene one plasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC. Genprex’s three lung cancer clinical programs have received a Fast Track Designation from the FDA for the treatment of that patient population, and Genprex’s SCLC program has received an FDA Orphan Drug Designation. Genprex’s diabetes gene therapy approach comprises a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body’s immune system. In a similar approach, GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells.


- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.